Forecast

The analysts' average price target is €16.81 (+9.73%). The median is €16.81 (+9.73%).

Buy	4
Hold	10
Sell	0

News Go to news feed

Kenvue pays quarterly dividend of $0.21 on Oct. 2

Kenvue's board of directors approved a quarterly dividend of $0.21 per common share. The payment will be made on October 2, 2026, to shareholders of record at the close of business on September 21, 2026. » More on de.investing.com
Kenvue raises quarterly dividend by 1.2% to $0.21

Kenvue has increased the quarterly dividend by 1.2% to $0.21 per common share. The payment will be made on August 26, 2026, to shareholders of record on August 12, 2026. Kenvue operates in the consumer health sector and owns brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena and Tylenol. » More on de.investing.com
Federal appeals court reinstates Tylenol lawsuits against Kenvue — stock falls

A three-judge panel in New York vacated the dismissal of suits against Kenvue and sent the case back for further proceedings, saying the lower court apparently exceeded its discretion when excluding three expert witnesses. Plaintiffs accuse Kenvue of concealing risks of a link between Tylenol use during pregnancy and autism; in 2023 about 500 suits had already been partly dismissed. Resuming the cases could lead to thousands more filings; a potential settlement could cost billions, Bloomberg Intelligence says. Kenvue shares fell about 1% on Monday. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Kenvue has already paid €0.54 in dividends. The last payout was in August.

Financials

In the last quarter, Kenvue had revenue of €3.47bn and net profit of €400.49m

(EUR)	June 2026	YoY
Revenue	3.47bn	6.10%
Gross profit	2.02bn	4.81%
Net profit	400.49m	11.82%
EBITDA	731.59m	2.50%

Fundamentals

Metric	Value
Market capitalization	€29.44bn
Number of shares	1.92bn
52-week high/low	€17.35 - €12.08
Dividend yield	4.65%
Dividends TTM	€0.71
Next dividend	€0.18
Beta	0.43
P/E ratio	20.45
PEG ratio	1.16
P/B ratio	3.24
P/S ratio	2.22

Company profile

Kenvue Inc. ist ein weltweit tätiges Unternehmen im Bereich der Verbrauchergesundheit. Das Unternehmen ist in drei Segmenten tätig: Self Care, Skin Health and Beauty und Essential Health. Das Segment Self Care bietet unter den Marken Tylenol, Nicorette und Zyrtec Produkte zur Behandlung von Husten, Erkältungen und Allergien, zur Schmerzbehandlung, für die Verdauung, zur Raucherentwöhnung und andere Produkte an. Das Segment Skin Health and Beauty bietet unter den Markennamen Neutrogena, Aveeno und OGX Gesichts- und Körperpflege, Haarpflege sowie Sonnen- und andere Pflegeprodukte an. Das Segment Essential Health bietet unter den Marken Listerine, Johnson's, Band-Aid und Stayfree Produkte für die Mund- und Babypflege, die Gesundheit von Frauen und die Wundpflege an. Das Unternehmen wurde im Jahr 2022 gegründet und hat seinen Hauptsitz in Skillman, New Jersey. Kenvue Inc. arbeitet als Tochtergesellschaft von Johnson & Johnson.

Name	Kenvue
CEO	Kirk L. Perry
Headquarters	Summit, nj USA
Website	kenvue.com
Sector	Consumer Staples
Industry	Consumer Staples Distribution & Retail
IPO	04/05/2023
Employees	21,890